Piromelatine

Piromelatine is a multimodal investigational small molecule drug developed primarily for the treatment of insomnia and Alzheimer's disease. It acts as an agonist at melatonin receptor MT1, melatonin receptor MT2, melatonin receptor MT3 and serotonin receptor 5-HT1A, serotonin receptor 5-HT1D, with additional low-affinity antagonism at serotonin receptor 5-HT2B, purinergic receptor P2X3, and transient receptor potential cation channel subfamily V member 1 (TRPV1). By targeting these pathways, piromelatine aims to regulate circadian rhythm, improve sleep quality, enhance cognition and mood, and potentially provide metabolic benefits such as improved insulin sensitivity. Preclinical studies have shown cognitive improvement in animal models of Alzheimer’s disease as well as antidepressant-like effects in stress models. Clinical trials have focused on its use for insomnia and Alzheimer's disease[1][3][4][5][6][7].

Brand names

Piromelatine